HCW Biologics is trading 11.1% down at $2.56, extending a steep multi-day slide amid continued downside momentum and profit-taking.
- The stock has seen a significant decline from its July 15 high of $4.30.
- There are no fresh company-specific announcements or major analyst actions driving today's move.
- The price action appears to reflect technical weakness in the micro-cap biotech name rather than new fundamental developments.